RA Fracture Risk Affected by Glucocorticoid Treatment

by U.S. Medicine

October 14, 2018

RICHMOND, VA—How much does systemic glucocorticoid exposure increase fracture among patients with newly-diagnosed inflammatory and immune-modulated conditions, including rheumatoid arthritis.

The study in the Journal of Bone and Mineral Research used administrative data to look at patients with RA, asthma/chronic obstructive pulmonary disease, inflammatory bowel disease, multiple sclerosis, lupus and sarcoidosis patients, aged 18 to 64. All had benefits coverage 12 or more months before diagnosis from Jan. 1, 2005, to Dec. 31, 2012, and the glucocorticoid users were new to therapy.1

The study team, including researchers from the McGuire VAMC in Richmond, followed the patients to either clinical fracture, cancer diagnosis, or Dec. 31, 2012.

Researchers noted that fracture incidence rates (IRs) per 1000 person-years were stratified by prednisone equivalent doses, and that models assessed risk by daily and cumulative dose, and by time since discontinuation, adjusted for baseline characteristics.

Results indicated that most patients (72% of 403,337) had glucocorticoid exposure; 52% were younger than 50. The risk of any osteoporotic fracture was elevated at doses greater than 5 mg/day (IR 9.33; 95% CI, 7.29 to 11.77) vs. 0 mg/day (IR 4.87 (95% CI, 4.72 to 5.02), the study found.

The increase in fracture rates affected both those under 50 and 50 and older, with a dose of more than 5 mg/day. In both age groups, fracture risk also increased with increasing cumulative exposure, being approximately 2.5-fold higher at cumulative dose of 5400 mg or greater compared to less than 675 mg.

At 5400 mg or greater cumulative dosage, the study determined that IR values were 5.69 (95% CI, 4.32 to 7.35) in patients younger than 50 and 17.10 (95% CI, 14.97 to 19.46) in older patients.

“Fracture risk decreased significantly within months following glucocorticoid discontinuation,” the researchers wrote. “In patients with a variety of inflammatory conditions, fracture risk increased at doses as low as <5 mg/day. Risk increased with increasing cumulative exposure and decreased soon following glucocorticoid discontinuation. Trends were similar between patients older and younger than 50 years.”

1. Balasubramanian A, Wade SW, Adler RA, Saag K, Pannacciulli N, Curtis JR. Glucocorticoid Exposure and Fracture Risk in a Cohort of US Patients With Selected Conditions. J Bone Miner Res. 2018 Jun 20. doi: 10.1002/jbmr.3523. [Epub ahead of print] PubMed PMID: 29924418.

Comments are closed here.

Related Articles

HIV Patients Had Lower PC Incidence in VA Study

NEW YORK—Non-AIDS defining cancers are increasingly important contributors to health outcomes for aging persons with HIV (PWH), according to a recent conference presentation which also pointed out that, although prostate cancer is prevalent in aging... View Article

VA Study Finds No Link Between ADT, Dementia

LA JOLLA, CA—Research has been conflicting on whether androgen deprivation therapy is related to dementia. A research letter in JAMA Oncology pointed out that two studies reported a strong statistically significant association between ADT and... View Article

U.S. Medicine Recommends

More From rheumatology


Target Lung Disease to Improve Rheumatoid Arthritis Survival

A recent VA study emphasized the importance of targeting comorbid lung disease to improve long-term outcomes in rheumatoid arthritis (RA).


Obesity, Weight-Loss Both Worsen RA U.S. Medicine

Obese patients with rheumatoid arthritis report greater disability in cross-sectional studies, but what that means over the long term has not been studied often.


Opioid Prescription Delays DMARD Initiation

What factors can cause delays in initiation of initial disease-modifying antirheumatic drug, or DMARD, in patients newly diagnosed with rheumatoid arthritis (RA)?


Not Enough Veterans Get Folic Acid With Methotrexate

SAN FRANCISCO—Co-prescription of folic acid in patients receiving low dose oral methotrexate (MTX) is recommended because it reduces adverse events and prolongs the use of the drug. A study on PLOS One suggests, however, that... View Article


PsA Patients Not at Increased Risk of Mortality, Except for Suicide

PHILADELPHIA—What are the common causes of mortality in patients with psoriatic arthritis (PsA) compared with the general population and compared with patients with rheumatoid arthritis (RA)? A report in the journal Rheumatology (Oxford) provided some... View Article

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up